贝伐珠单抗联合化学药物治疗晚期胃癌的疗效观察(1)
摘 要：目的 研究贝伐珠单抗联合化学药物应用于晚期胃癌患者的安全性评价与临床疗效观察。方法 选取我院2014年1月～2017年6月收治的64例晚期胃癌患者作为研究对象，随机均分为联合组和化疗组，各32例。化疗组行常规化学药物治疗采用奥沙利铂、亚叶酸钙和氟尿嘧啶的治疗方法，实验组在常规治疗的基础上行贝伐珠单抗联合治疗，即静脉推注7.5 mg/kg的贝伐珠单抗。两组均连续治疗3个疗程，每个疗程的时长为21 d。比较两组患者治疗前后血清肿瘤标志物水平、药物毒副作用情况和近期的综合疗效观察及患者生存质量情况。结果 血清肿瘤标志物水平治疗前>化疗组>联合组，差异有统计学意义(P<0.05)，联合组疗效、生存质量高于化疗组，差异有统计学意义(P<0.05)。联合组患者无毒副作用发生率与联合组，差异无统计学意义(P>0.05)。结论 采用贝伐珠单抗联合化学药物治疗晚期胃癌患者有显著的临床疗效，不增加毒副作用，值得在临床上推广使用。
关键词：贝伐珠单抗联合化学药物；晚期胃癌；疗效观察；安全性评价
, 百拇医药
中图分类号：R735.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.08.043
文章编号：1006-1959(2018)08-0128-03
Efficacy of Bevacizumab Combined with Chemical Drugs in the Treatment of Advanced Gastric Cancer
WANG Guo-fu
(Department of Oncology，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China)
Abstract：Objective To study the safety evaluation and clinical efficacy of bevacizumab combined with chemical drugs in patients with advanced gastric cancer.Methods 64 patients with advanced gastric cancer admitted in our hospital from January 2014 to June 2017 were randomly divided into combined group and chemotherapy group(32 cases each).The chemotherapy group was treated with oxaliplatin， calcium folinate and fluorouracil.The experimental group was treated with bevacizumab on the basis of routine therapy， that is， the bevacizumab of 7.5 mg/kg was injected intravenously.The two groups were treated continuously for 3 courses，the duration of each course was 21 d.The levels of serum tumor markers，the side effects of drugs，the recent comprehensive efficacy and the quality of life of the two groups before and after treatment were compared.Results The level of serum tumor markers before treatment> chemotherapy group>combined group，the difference was statistically significant(P<0.05).The curative effect and quality of life of the combined group were higher than that of the chemotherapy group，and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of no toxic side effects between the combined group and the combined group(P>0.05). Conclusion The combination of bevacizumab and chemotherapeutic drugs is effective in the treatment of advanced gastric cancer without increasing side effects and is worth popularizing in clinic.
, 百拇医药
Key words：Bevacizumab combined with chemical drugs；Advanced gastric cancer；Efficacy observation；Safety evaluation
胃癌(gastric cancer)在我國的发病率和病死率均为恶性肿瘤之首，好发于50岁以上的中老年人，一般男性居多。早期胃癌患者一般无明显症状，少数出现恶心、呕吐等类似溃疡病的症状，并且早期胃癌难以诊断。大多数患者在确诊时已步入晚期，错失了外科手术切除根治的绝佳时机。对于胃癌晚期患者，多数医生建议采用药物治疗等保守治疗，以防止病情进一步恶化。目前，临床上对胃癌晚期患者主要的治疗方法是化疗，但是如果仅仅只给予化学治疗，一般患者的耐受性较差，因此产生的毒副作用也较大，极大程度地降低了治疗效果，甚至有恶化的可能。贝伐珠单抗是近几年临床上新出现的抗肿瘤药物，是一种通过分子靶向的方式实现抗肿瘤目的的药物。在目前的研究报道和数据来看，贝伐珠单抗具有良好的抗肿瘤效果[1]。本研究通过观察本院2014年1月～2017年6月收治的64例晚期胃癌患者的病情进展，探讨贝伐珠单抗联合化学药物治疗胃癌晚期的疗效与安全性评价。, 百拇医药(王国富)
关键词：贝伐珠单抗联合化学药物；晚期胃癌；疗效观察；安全性评价
, 百拇医药
中图分类号：R735.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.08.043
文章编号：1006-1959(2018)08-0128-03
Efficacy of Bevacizumab Combined with Chemical Drugs in the Treatment of Advanced Gastric Cancer
WANG Guo-fu
(Department of Oncology，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China)
Abstract：Objective To study the safety evaluation and clinical efficacy of bevacizumab combined with chemical drugs in patients with advanced gastric cancer.Methods 64 patients with advanced gastric cancer admitted in our hospital from January 2014 to June 2017 were randomly divided into combined group and chemotherapy group(32 cases each).The chemotherapy group was treated with oxaliplatin， calcium folinate and fluorouracil.The experimental group was treated with bevacizumab on the basis of routine therapy， that is， the bevacizumab of 7.5 mg/kg was injected intravenously.The two groups were treated continuously for 3 courses，the duration of each course was 21 d.The levels of serum tumor markers，the side effects of drugs，the recent comprehensive efficacy and the quality of life of the two groups before and after treatment were compared.Results The level of serum tumor markers before treatment> chemotherapy group>combined group，the difference was statistically significant(P<0.05).The curative effect and quality of life of the combined group were higher than that of the chemotherapy group，and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of no toxic side effects between the combined group and the combined group(P>0.05). Conclusion The combination of bevacizumab and chemotherapeutic drugs is effective in the treatment of advanced gastric cancer without increasing side effects and is worth popularizing in clinic.
, 百拇医药
Key words：Bevacizumab combined with chemical drugs；Advanced gastric cancer；Efficacy observation；Safety evaluation
胃癌(gastric cancer)在我國的发病率和病死率均为恶性肿瘤之首，好发于50岁以上的中老年人，一般男性居多。早期胃癌患者一般无明显症状，少数出现恶心、呕吐等类似溃疡病的症状，并且早期胃癌难以诊断。大多数患者在确诊时已步入晚期，错失了外科手术切除根治的绝佳时机。对于胃癌晚期患者，多数医生建议采用药物治疗等保守治疗，以防止病情进一步恶化。目前，临床上对胃癌晚期患者主要的治疗方法是化疗，但是如果仅仅只给予化学治疗，一般患者的耐受性较差，因此产生的毒副作用也较大，极大程度地降低了治疗效果，甚至有恶化的可能。贝伐珠单抗是近几年临床上新出现的抗肿瘤药物，是一种通过分子靶向的方式实现抗肿瘤目的的药物。在目前的研究报道和数据来看，贝伐珠单抗具有良好的抗肿瘤效果[1]。本研究通过观察本院2014年1月～2017年6月收治的64例晚期胃癌患者的病情进展，探讨贝伐珠单抗联合化学药物治疗胃癌晚期的疗效与安全性评价。, 百拇医药(王国富)